Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte Corporation (INCY) Presents at Jefferies London Healthcare Conference 2025 Transcript
01:48pm, Tuesday, 18'th Nov 2025
Incyte Corporation ( INCY ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
04:05pm, Monday, 17'th Nov 2025
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL).
Incyte Corporation (INCY) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
01:51pm, Monday, 10'th Nov 2025
Incyte Corporation ( INCY ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnon
Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
09:15am, Thursday, 06'th Nov 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema.
Top Biotech Stocks Riding The Rally
03:15pm, Tuesday, 04'th Nov 2025
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock pric
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
07:01am, Tuesday, 04'th Nov 2025
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
09:31am, Monday, 03'rd Nov 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting.
Bessemer Group Inc. Reduces Stock Holdings in Incyte Corporation $INCY
03:35am, Monday, 03'rd Nov 2025
Bessemer Group Inc. reduced its stake in Incyte Corporation (NASDAQ: INCY) by 60.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissi
Incyte to Present at Upcoming Investor Conferences
08:00am, Thursday, 30'th Oct 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation
4 Best Value And Growth Stocks (Yes, They Can Coexist)
08:00am, Thursday, 30'th Oct 2025
The current market is all about momentum, but investors don't need to buy overpriced high-growth stocks to participate in gains. If you dig deep enough, you can find undervalued stocks with growth pot
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
07:30am, Thursday, 30'th Oct 2025
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Labo
Asset Management One Co. Ltd. Has $5.94 Million Stock Position in Incyte Corporation $INCY
03:38am, Wednesday, 29'th Oct 2025
Asset Management One Co. Ltd. lowered its position in shares of Incyte Corporation (NASDAQ: INCY) by 3.1% in the second quarter, according to the company in its most recent 13F filing with the Securit
Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio
05:51pm, Tuesday, 28'th Oct 2025
Incyte Corporation remains a Buy supported by strong Q3 2025 earnings, robust revenue growth, and raised full-year 2025 guidance. INCY advances its pipeline with promising data for povorcitinib in HS,
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
02:44pm, Tuesday, 28'th Oct 2025
Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.
